Dec 10 (Reuters) - Spruce Biosciences (SPRB.O), opens new tab said on Tuesday it will wind down investments for its genetic disorder drug after it failed in a mid-stage trial, sending its shares down ...
SOUTH SAN FRANCISCO, Calif. & MUNICH--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel ...
HMNC will fund and conduct a Phase 2 proof-of-concept study of tildacerfont in MDD patients, who will be screened using Cortibon. Spruce has the option to in-license exclusive worldwide rights to ...
On Tuesday, Spruce Biosciences, Inc. (NASDAQ:SPRB) revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric ...
Hosted on MSN
Spruce Biosciences reports positive FDA meetings as it prepares TA-ERT filing for rare pediatric disorder
Spruce Biosciences, Inc. (NASDAQ:SPRB) said it has completed two Type B meetings with the U.S. Food and Drug Administration (FDA), clearing key regulatory discussions ahead of its planned biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results